General Information of Drug (ID: DMYPXQ2)

Drug Name
CVBT-141H Drug Info
Synonyms
CVBT-141A; CVBT-141C; CVBT-141C); Cardio Vascu-Grow; FGF-1-141; Recombinant FGF-1 (coronary heart disease), CardioVascular Therapeutics; Recombinant FGF-1 (peripheral vascular disease), CardioVascular biotherapeutics
Indication
Disease Entry ICD 11 Status REF
Coronary artery disease BA80 Phase 2 [1]
Coronary heart disease BA80.Z Phase 2 [2]
Peripheral arterial disease BD4Z Phase 2 [2]
Cross-matching ID
TTD Drug ID
DMYPXQ2

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Discontinued Drug(s)
Investigative Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Riferminogene pecaplasmid DMBKN4P Critical limb ischemia BD4Y Discontinued in Phase 3 [4]
Formic Acid DMNFZC6 Discovery agent N.A. Investigative [5]
N,O6-Disulfo-Glucosamine DMYCV7U Discovery agent N.A. Investigative [5]
O2-Sulfo-Glucuronic Acid DME78MS Discovery agent N.A. Investigative [5]
Naphthalene Trisulfonate DML6FI3 Discovery agent N.A. Investigative [5]
5-AMINO-NAPHTALENE-2-MONOSULFONATE DMYTUNE Discovery agent N.A. Investigative [6]
Sucrose Octasulfate DMET64R Discovery agent N.A. Investigative [5]
⏷ Show the Full List of 7 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Heparin-binding growth factor 1 (FGF1) TTMY81X FGF1_HUMAN Modulator [3]

References

1 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800020529)
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3 Clinical pipeline report, company report or official report of CVBT.
4 Riferminogene pecaplasmide. Am J Cardiovasc Drugs. 2010;10(5):343-6.
5 How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
6 The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.